Reports preliminary FY25 revenue $4.15B, consensus $3.59B. “Argenx (ARGX) enters 2026 in a position of strength, delivering meaningful impact to approximately 19,000 patients globally while advancing a world-class pipeline toward Vision 2030,” said Tim Van Hauwermeiren, CEO of Argenx. “With Vyvgart leading the growth of all biologics in MG and CIDP, we are proving the power of our approach: to redefine treatment paradigms through disciplined evidence generation and to redefine patient outcomes with medicines that are both more effective and more convenient. This same playbook will guide our future, as we aim to launch a portfolio of new medicines that could transform the lives of more than 50,000 patients across 10 indications.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target raised to $1,030 from $950 at Truist
- Argenx price target raised to $1,160 from $1,110 at Morgan Stanley
- Argenx price target lowered to $1,091 from $1,124 at Citi
- Argenx price target raised to EUR 880 from EUR 850 at Barclays
- Immunovant upgraded to Outperform at Wolfe on improving Graves’ perception